Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 主要终点
- Mean Latency to Persistent Sleep
研究概览
简要总结
The present study was conducted to investigate the impact of diphenhydramine hydrochloride on the ability to initiate sleep.
详细描述
Diphenhydramine hydrochloride (herein referred to as diphenhydramine) is an antihistamine of the ethanolamine classes with known sleep-inducing properties and is approved by the Food & Drug Administration to reduce the time to sleep onset in individuals having difficulty falling asleep. The goal of the study is to investigate diphenhydramine versus placebo with regard to several sleep parameters, including time to sleep onset, in healthy adult subjects suffering from occasional sleeplessness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month;
- •be in good general health without clinically significant disease (no previously diagnosed sleep disorders);
- •if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study
排除标准
- •have a clinically significant illness within 30 days of Screening;
- •are taking medication that could interfere with the study medication;
- •have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia;
- •are currently taking medications known to effect sleep function;
- •have current or past history of serious, severe or unstable physical or psychiatric illness;
- •have current diagnosis of severe urinary retention;
- •have current diagnosis of untreated narrow angle glaucoma;
- •had participated in a clinical drug study or used an investigational new drug during the previous 30 days;
- •have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;
研究组 & 干预措施
Diphenhydramine Hydrochloride
Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
干预措施: Diphenhydramine Hydrochloride (Drug)
Placebo
Placebo elixir taken when subjects had trouble falling asleep
干预措施: Placebo (Drug)
结局指标
主要结局
Mean Latency to Persistent Sleep
时间窗: 4 weeks
Per Protocol population based on subjects who completed treatment crossover
次要结局
未报告次要终点